Ozempic Shows Promise for Kidneys and Heart Health

Millions of people with chronic kidney disease just got hopeful news about a medication already sitting in many medicine cabinets.

Semaglutide, the drug sold as Ozempic and Wegovy, is doing far more than helping people lose weight. New research published today shows it significantly improves kidney function and survival rates in people with type 2 diabetes and chronic kidney disease, even if they already have heart disease.

Lead researcher Katherine Tuttle from the University of Washington calls semaglutide "a highly kidney protective therapy." People taking the drug once weekly showed improved kidney function and were more likely to stay off dialysis.

The findings build on previous research showing the drug prevents heart attacks, strokes, and cardiovascular deaths in high-risk patients. For people juggling diabetes, kidney disease, and heart problems, this represents a major breakthrough.

About 2.7 million Australian adults show signs of chronic kidney disease, though most don't know it until symptoms appear in advanced stages. These patients face high risks of kidney failure, heart complications, and early death.

The Bright Side

The drug works by targeting multiple connected health problems at once. James Tang, a kidney specialist at St Vincent's Hospital, explains that diabetes, kidney disease, heart problems, and obesity are all interconnected.

By helping manage blood sugar and weight, semaglutide creates a positive ripple effect throughout the body. The kidneys benefit as diabetes and obesity become better controlled.

While scientists still need to understand exactly how the drug protects kidneys, the real-world results speak for themselves. Last year, Australia's medical regulator approved Ozempic specifically for reducing kidney disease progression in people with type 2 diabetes and chronic kidney disease.

The study analyzed data from patients who took semaglutide weekly. Even those with previous heart attacks, strokes, or heart failure saw meaningful improvements in kidney function and survival.

Natalie Raffoul from the Heart Foundation notes that while pharmaceutical company Novo Nordisk funded the research, this is standard practice for major drug trials. Independent clinical and academic groups oversee the work to maintain integrity.

For patients managing multiple serious health conditions, this research offers something precious: hope that one treatment might protect several vital organs at once.